These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 33937032)

  • 1. Preclinical Evaluation of Carfilzomib for Infant
    Cheung LC; de Kraa R; Oommen J; Chua GA; Singh S; Hughes AM; Ferrari E; Ford J; Chiu SK; Stam RW; Kees UR; Malinge S; Kotecha RS
    Front Oncol; 2021; 11():631594. PubMed ID: 33937032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
    Swift L; Jayanthan A; Ruan Y; Anderson R; Boklan J; Trippett T; Narendran A
    Target Oncol; 2018 Dec; 13(6):779-793. PubMed ID: 30446871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
    Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
    Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
    Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
    Front Oncol; 2022; 12():863329. PubMed ID: 35677155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine mildly attenuates
    Schneider P; Castro PG; Pinhanços SM; Kerstjens M; van Roon EH; Essing AHW; Dolman MEM; Molenaar JJ; Pieters R; Stam RW
    EJHaem; 2020 Nov; 1(2):527-536. PubMed ID: 35844991
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia.
    Burke MJ; Ziegler DS; Bautista F; Attarbaschi A; Gore L; Locatelli F; M O'Brien M; Pauly M; Kormany WN; Tian S; Morris CL; Baruchel A
    Pediatr Blood Cancer; 2022 Dec; 69(12):e29999. PubMed ID: 36215217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Throughput Drug Library Screening in Primary
    Wander P; Arentsen-Peters STCJM; Vrenken KS; Pinhanҫos SM; Koopmans B; Dolman MEM; Jones L; Garrido Castro P; Schneider P; Kerstjens M; Molenaar JJ; Pieters R; Zwaan CM; Stam RW
    Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
    Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
    Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric
    Kerstjens M; Garrido Castro P; Pinhanços SS; Schneider P; Wander P; Pieters R; Stam RW
    Biomedicines; 2021 Jun; 9(7):. PubMed ID: 34201500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line.
    Hosseini MS; Mohammadi MH; Vahabpour Roudsari R; Jafari L; Mashati P; Gharehbaghian A
    Iran J Pharm Res; 2019; 18(Suppl1):132-145. PubMed ID: 32802094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic
    Karsa M; Ronca E; Bongers A; Mariana A; Moles E; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Kavallaris M; Haber M; Norris MD; Henderson MJ; Xiao L; Somers K
    Front Oncol; 2021; 11():779859. PubMed ID: 35127484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
    Brown PA; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang C; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz MJ; Small D; Loh ML; Hunger SP
    Leukemia; 2021 May; 35(5):1279-1290. PubMed ID: 33623141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
    Popov A; Tsaur G; Permikin Z; Henze G; Verzhbitskaya T; Plekhanova O; Nokhrina E; Valochnik A; Sibiryakov P; Zerkalenkova E; Olshanskaya Y; Gindina T; Movchan L; Shorikov E; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30204. PubMed ID: 36715125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
    Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
    Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
    Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
    Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
    Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
    BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
    Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
    Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
    Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
    J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.
    Guest EM; Kairalla JA; Devidas M; Hibbitts E; Carroll AJ; Heerema NA; Kubaney HR; August MA; Ramesh S; Yoo B; Farooqi MS; Pauly MG; Wechsler DS; Miles RR; Reid JM; Kihei CD; Gore L; Raetz EA; Hunger SP; Loh ML; Brown PA
    Haematologica; 2024 Jun; ():. PubMed ID: 38867582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia.
    Richter A; Lange S; Holz C; Brock L; Freitag T; Sekora A; Knuebel G; Krohn S; Schwarz R; Hinz B; Murua Escobar H; Junghanss C
    Cell Death Discov; 2022 Jul; 8(1):302. PubMed ID: 35778418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.